Andy Eckert appointed incoming Chair; Founder Dr. Miroslav Reljanovic retires.
Guildford, Surrey UK, April 07, 2026 -- Ergomed Group, a global professional services partner to the biopharmaceutical industry, today announced a planned transition in its Board Chair role. Andy Eckert has been appointed as incoming Chair of the Board, following the decision of Dr. Miroslav Reljanovic, Ergomed Group’s founder, to retire from the Board and his role as Chair.
Dr. Reljanovic founded Ergomed and has been instrumental in shaping the company’s strategy, values, and long term direction since its inception. Under his leadership, Ergomed has grown into a global organisation with a strong reputation for quality, governance, and client service. The Board extends its sincere gratitude to Dr. Reljanovic for his outstanding contribution and legacy.
Andy Eckert brings deep experience in healthcare, life sciences, and technology enabled services, having served in senior executive and Board Chair roles across global organisations. Mr. Eckert’s insights, and extensive background in healthcare, will be an asset as the Board supports the executive leadership team’s efforts to drive differentiation that will advance each brand’s market position.
He has worked closely with Permira, Ergomed’s majority shareholder, as a Senior Advisor since 2022. As Chair, Andy will focus on strong governance, strategic oversight, and supporting the management team as Ergomed Group continues to execute its strategy.
“Ergomed Group is a high quality business with a strong platform, differentiated capabilities, and an incredible client base. I am delighted to join as Chair at this important point in its evolution. I look forward to working closely with the Board and management team to build on this progress, support the company’s strategic priorities, and help drive continued growth and value creation.”
To support leadership continuity during this period of transition, the Board has also appointed Zubair Javeed as Interim CEO, effective April 7. Zubair will continue to serve as Chief Financial Officer alongside this appointment, ensuring continuity across leadership and financial stewardship. He will work closely with the Executive Leadership Team to ensure stability, alignment, and uninterrupted focus on operational execution.
“I am honored to step into the role of Interim CEO. Ergomed Group is a strong business with great fundamentals and clear priorities. Our focus is on maintaining momentum, executing with discipline, and continuing to deliver for our customers and partners.”
This appointment follows a previously communicated leadership update related to Sy Pretorius, Ergomed Group’s outgoing CEO, who will remain with the business through the end of April to support an orderly transition.
Ergomed Group remains committed to commercializing a portfolio of highly specialized, best-in-class solutions that make safe and life-changing pharmaceutical-led care accessible to patients around the world.
